Yarrow Bioscience (NASDAQ:YARW) Releases Quarterly Earnings Results

Yarrow Bioscience (NASDAQ:YARW) announced its quarterly earnings data on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, FiscalAI reports. Yarrow Bioscience had a negative net margin of 4,726.21% and a negative return on equity of 84.40%.

Yarrow Bioscience Stock Performance

YARW stock traded up $0.59 on Thursday, reaching $18.64. 41,721 shares of the company’s stock were exchanged, compared to its average volume of 48,896. The company has a fifty day moving average of $22.30. Yarrow Bioscience has a twelve month low of $12.39 and a twelve month high of $46.95. The company has a market cap of $49.78 million, a price-to-earnings ratio of -1.27 and a beta of 2.10.

Institutional Investors Weigh In On Yarrow Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new position in shares of Yarrow Bioscience in the 2nd quarter valued at about $26,000. BlackRock Inc. acquired a new stake in shares of Yarrow Bioscience in the second quarter valued at about $29,000. Nantahala Capital Management LLC purchased a new stake in Yarrow Bioscience during the second quarter worth about $1,301,400,000. GSA Capital Partners LLP purchased a new stake in Yarrow Bioscience during the second quarter worth about $47,000. Finally, Braidwell LP purchased a new stake in Yarrow Bioscience during the second quarter worth about $596,000. Institutional investors and hedge funds own 83.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. BTIG Research assumed coverage on Yarrow Bioscience in a research note on Monday, August 3rd. They set a “buy” rating and a $58.00 target price for the company. TD Cowen assumed coverage on Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a “buy” rating on the stock. Guggenheim began coverage on Yarrow Bioscience in a research note on Friday, November 6th. They issued a “buy” rating and a $60.00 price objective for the company. Finally, Wall Street Zen upgraded Yarrow Bioscience to a “hold” rating in a research note on Saturday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Yarrow Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $59.00.

About Yarrow Bioscience

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.